Home » Stocks » AstraZeneca

AstraZeneca plc (AZN)

Stock Price: $55.19 USD -0.61 (-1.09%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $55.28 +0.09 (0.16%) Aug 14, 7:59 PM

Stock Price Chart

Key Info

Market Cap 144.85B
Revenue (ttm) 25.70B
Net Income (ttm) 2.05B
Shares Out 2.62B
EPS (ttm) 0.82
PE Ratio 67.30
Forward PE 28.01
Dividend $1.40
Dividend Yield 2.54%

Stock Quote

Trading Day Aug 14, 2020
Last Price $55.19
Previous Close $55.80
Change ($) -0.61
Change (%) -1.09%
Day's Open 55.47
Day's Range 55.05 - 55.60
Day's Volume 2,948,674
52-Week Range 36.15 - 64.94

More Stats

Market Cap 144.85B
Enterprise Value 158.48B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date Aug 13, 2020
Shares Outstanding 2.62B
Float 2.62B
EPS (basic) 0.82
EPS (diluted) 0.82
FCF / Share 1.49
Dividend $1.40
Dividend Yield 2.54%
Earnings Yield 1.49%
FCF Yield 2.71%
Payout Ratio n/a
Shares Short 1.24M
Short Ratio 0.66
Short % of Float n/a
Beta 0.26
PE Ratio 67.30
Forward PE 28.01
P/FCF Ratio 36.96
PS Ratio 5.64
PB Ratio 11.97
Revenue 25.70B
Operating Income 3.84B
Net Income 2.05B
Free Cash Flow 3.92B
Net Cash -13.63B
Net Cash / Share -5.19
Gross Margin 76.02%
Operating Margin 14.93%
Profit Margin 8.00%
FCF Margin 15.25%
ROA 4.47%
ROE 14.24%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (24)

Buy 15
Overweight 0
Hold 4
Underweight 2
Sell 3

Analyst Consensus: Overweight

Price Target

$58.40*
(5.82% upside)
Low
41.2
Current: $55.19
High
68.5
Target: 58.40
*Average 12-month price target from 21 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue24,38422,09022,46523,00224,70826,54725,80627,97333,59133,269
Revenue Growth10.38%-1.67%-2.33%-6.9%-6.93%2.87%-7.75%-16.72%0.97%-
Gross Profit19,46317,15418,14718,87620,06220,70520,54522,58027,56526,880
Operating Income2,9243,3873,6774,9024,1142,1373,7128,14811,31211,494
Net Income1,2272,0502,8683,4062,8261,2352,5716,2709,9508,081
Shares Outstanding1,3011,2671,2661,2651,2641,2621,2521,2611,3611,438
Earnings Per Share0.520.851.191.381.120.491.022.473.632.79
EPS Growth-39.41%-28.27%-14.13%23.77%127.55%-51.96%-58.7%-31.86%30.16%-
Dividend Per Share1.401.401.401.402.352.802.802.852.702.41
Dividend Growth0%0%0%-40.43%-16.07%0%-1.75%5.56%12.03%-
Operating Cash Flow4,8613,8314,7305,2345,1748,7928,7199,53612,36813,854
Capital Expenditures-942-1,031-1,243-1,364-1,281-854-673-473-737-708
Free Cash Flow3,9192,8003,4873,8703,8937,9388,0469,06311,63113,146
Cash & Equivalents6,2185,6804,5545,9026,8537,15510,0138,52411,81912,550
Total Debt18,22719,11317,80716,80815,05310,84310,37610,3109,3289,222
Net Cash / Debt-12,009-13,433-13,253-10,906-8,200-3,688-363-1,7862,4913,328
Assets61,37760,65163,35462,52660,05658,59555,89953,53452,83056,127
Liabilities46,78146,60746,71245,85741,54738,94932,64629,58829,36432,717
Book Value13,12712,46814,96014,85418,49019,62723,22423,73123,24023,213
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AstraZeneca plc
Country United Kingdom
Employees 70,600
CEO Pascal Soriot

Stock Information

Ticker Symbol AZN
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: AZN
IPO Date May 12, 1993

Description

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.